Track Day One Biopharmaceuticals's total assets ($510M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Day One Biopharmaceuticals posts a total assets of $510M as of December 2025. That compares with $580M in the prior-year period — down 12.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Day One Biopharmaceuticals's total assets was $580M. The latest reading is $510M — a 12.9% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.
Total Assets is one piece of Day One Biopharmaceuticals's financial statement story. At $510M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for DAWN's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Day One Biopharmaceuticals's other metric pages and overview cover the third.
Judging Day One Biopharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $510M here, then scan peer and history charts to see if the gap is persistent.